RTTNews | Dec 11, 2020 08:16AM EST

08:16 Friday, December 11, 2020 (RTTNews.com) - Lexicon Pharmaceuticals, Inc. (LXRX) has received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1).

The company is currently enrolling patients with diabetic peripheral neuropathic pain in a phase 2 proof-of-concept study of LX9211 and is preparing to initiate a second phase 2 clinical trial of LX9211 in post-herpetic neuralgia.

Praveen Tyle, executive vice president of research and development, said: "We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible."

Read the original article on RTTNews ( https://www.rttnews.com/3153053/lexicon-pharma-lx9211-receives-fast-track-designation-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved